

## Reviewers for 1993

We wish to acknowledge the important assistance we have received from many scientists who, along with the Editorial Board, have evaluated manuscripts submitted

for publication during 1993. All outside reviewers are listed in the December issue of *Psychiatry Research* (Volume 49, Number 3, 1993).

## Author Index for 1993

- Abbruzzese, M. 50:45  
Alliger, R. 50:283  
Almas, M. 50:25  
Andreasen, N.C. 50:283  
Arndt, S. 50:283  
Asarnow, R.F. 50:33  
Bartzokis, G. 50:33  
Bonfanti, A. 50:45, 50:89  
Calabrese, G. 50:89  
Calabrese, J. 50:77  
Cardwell, D. 50:67  
Chan, S. 50:143  
Cohen, G. 50:283  
Colombo, C. 50:45, 50:89  
Coppola, R. 50:177  
Cosyns, P. 50:77  
Daniel, D.G. 50:177  
DeCaria, C.M. 50:25, 50:143  
Degreef, G. 50:193  
DeLisi, L.E. 50:193  
Devous, M.D., Sr. 50:233  
Dierckx, R. 50:77  
Dierks, T. 50:151  
Eckardt, M.J. 50:101  
Engel, R. 50:163  
Ericson, K. 50:15  
Eriksson, L. 50:15  
Farde, L. 50:1  
Fink, G. 50:93  
Fredrikson, M. 50:15  
Frölich, L. 50:151  
Fukuda, H. 50:217  
Fukui, S. 50:217  
Fukuyama, H. 50:203  
Giunta, R. 50:163  
Granholm, E. 50:33  
Grannemann, B.D. 50:233  
Greitz, T. 50:15  
Günther, W. 50:163  
Gullion, C.M. 50:233  
Haag, C. 50:163  
Halldin, C. 50:1  
Harris, G.J. 50:57  
Heiss, W.-D. 50:93  
Herholz, K. 50:93  
Hilal, S. 50:143  
Hindmarsh, T. 50:1  
Hoff, A.L. 50:193  
Hollander, E. 50:25, 50:143  
Ihl, R. 50:151  
Ingels, M. 50:77  
Ishikura, S. 50:203  
Itoh, T. 50:217  
Iyo, M. 50:217  
John, E.R. 50:25  
Jonitz, L. 50:163  
Joyce, E.M. 50:101  
Karson, C.N. 50:67  
Kato, T. 50:203  
Klages, U. 50:163  
Klein, D.F. 50:143  
Koenig, T. 50:275  
Komorowski, R.A. 50:67  
Kushner, M. 50:193  
Lehmann, D. 50:275  
Levine, R.H. 50:25  
Liebowitz, M. 50:25  
Liebowitz, M.R. 50:143  
Lim, K.O. 50:257  
Litton, J.-E. 50:1  
Livian, S. 50:45  
Locatelli, M. 50:45  
Maes, M. 50:77  
Marder, S.R. 50:33  
Marenco, S. 50:177  
Mas, F. 50:25  
Mathalon, D.H. 50:121, 50:257, 50:284  
Maurer, K. 50:151  
Meltzer, H.Y. 50:77  
Michel, C.M. 50:275  
Mielke, R. 50:93  
Mohanakrishnan, P. 50:67

- Morita, R. 50:203  
Narita, M. 50:203  
Neiman, J. 50:1  
Newton, J.E.O. 50:67  
Nishio, M. 50:217  
Ohnishi, H. 50:203  
Pauli, S. 50:1  
Pearlson, G.D. 50:57  
Pfefferbaum, A. 50:121, 50:257, 50:284  
Prichep, L.S. 50:25  
Rawles, J.M. 50:121, 50:284  
Rio, D.E. 50:101  
Ritter, D. 50:93  
Rosenbloom, M.J. 50:257  
Rush, A.J. 50:233  
Ruttimann, U.E. 50:101  
Satoh, K. 50:203  
Satzger, W. 50:163  
Scarone, S. 50:45, 50:89  
Schotte, C. 50:77  
Scotti, G. 50:45, 50:89  
Sedvall, G. 50:1  
Shear, P.K. 50:257  
Shibasaki, M. 50:203  
Sprigg, J.R. 50:67  
Stein, D.J. 50:143  
Steinberg, R. 50:163  
Stone-Elander, S. 50:15  
Sullivan, E.V. 50:121, 50:257, 50:284  
Suzuki, K. 50:217  
Suzuki, T. 50:203  
Swayze, V.W. III 50:283  
Takahashi, S. 50:203  
Tateno, Y. 50:217  
Trivedi, M.H. 50:233  
Vandewoude, M. 50:77  
Wackermann, J. 50:275  
Weinberger, D.R. 50:177  
Wik, G. 50:15  
Yamasaki, T. 50:217  
Zigun, J.R. 50:177

## Subject Index for 1993

### Affective disorder

- aging, regional cerebral blood flow, 50:233
- aging, single photon emission computed tomography, 50:233
- aging, unipolar depression, 50:233
- frontal lobes, regional cerebral blood flow, 50:77
- frontal lobes, single photon emission computed tomography, 50:77
- frontal lobes, unipolar depression, 50:77
- regional cerebral blood flow, aging, 50:233
- regional cerebral blood flow, frontal lobes, 50:77
- regional cerebral blood flow, unipolar depression, 50:77, 50:233
- single photon emission computed tomography, aging, 50:233
- single photon emission computed tomography, frontal lobes, 50:77
- single photon emission computed tomography, unipolar depression, 50:77, 50:233
- unipolar depression, aging, 50:233
- unipolar depression, frontal lobes, 50:77
- unipolar depression, regional cerebral blood flow, 50:77, 50:233
- unipolar depression, single photon emission computed tomography, 50:77, 50:233

### Aging

- affective disorder, regional cerebral blood flow, 50:233
- affective disorder, single photon emission computed tomography, 50:233
- alcohol dependence, cerebrospinal fluid volume, 50:257
- alcohol dependence, computed tomography, 50:257
- alcohol dependence, magnetic resonance imaging, 50:257
- alcohol dependence, ventricle-brain ratio, 50:257
- Alzheimer's disease, dipole analysis, 50:151
- Alzheimer's disease, electroencephalography, 50:151, 50:163
- Alzheimer's disease, motor performance, 50:163
- Alzheimer's disease, music perception, 50:163
- Alzheimer's disease, spectral analysis, 50:151
- Alzheimer's disease, temporal lobes, 50:163
- basal ganglia, frontal lobes, 50:93
- basal ganglia, myotonic dystrophy, 50:93
- basal ganglia, positron emission tomography, 50:93
- cerebrospinal fluid volume, alcohol dependence, 50:257

### Aging continued

- cerebrospinal fluid volume, computed tomography, 50:257
- cerebrospinal fluid volume, magnetic resonance imaging, 50:257
- cerebrospinal fluid volume, ventricle-brain ratio, 50:257
- computed tomography, alcohol dependence, 50:257
- computed tomography, cerebrospinal fluid volume, 50:257
- computed tomography, magnetic resonance imaging, 50:257
- computed tomography, ventricle-brain ratio, 50:257
- dipole analysis, Alzheimer's disease, 50:151
- dipole analysis, electroencephalography, 50:151
- dipole analysis, spectral analysis, 50:151
- electroencephalography, Alzheimer's disease, 50:151, 163
- electroencephalography, dipole analysis, 50:151
- electroencephalography, motor performance, 50:163
- electroencephalography, music perception, 50:163
- electroencephalography, spectral analysis, 50:151
- electroencephalography, temporal lobes, 50:163
- frontal lobes, basal ganglia, 50:93
- frontal lobes, myotonic dystrophy, 50:93
- frontal lobes, positron emission tomography, 50:93
- magnetic resonance imaging, alcohol dependence, 50:257
- magnetic resonance imaging, cerebrospinal fluid volume, 50:257
- magnetic resonance imaging, computed tomography, 50:257
- magnetic resonance imaging, ventricle-brain ratio, 50:257
- motor performance, Alzheimer's disease, 50:163
- motor performance, electroencephalography, 50:163
- motor performance, temporal lobes, 50:163
- music perception, Alzheimer's disease, 50:163
- music perception, electroencephalography, 50:163
- myotonic dystrophy, basal ganglia, 50:93
- myotonic dystrophy, frontal lobes, 50:93
- myotonic dystrophy, positron emission tomography, 50:93

**Aging continued**

- positron emission tomography, basal ganglia, 50:93
- positron emission tomography, frontal lobes, 50:93
- positron emission tomography, myotonic dystrophy, 50:93
- regional cerebral blood flow, affective disorder, 50:233
- regional cerebral blood flow, unipolar depression, 50:233
- single photon emission computed tomography, affective disorder, 50:233
- single photon emission computed tomography, unipolar depression, 50:233
- spectral analysis, Alzheimer's disease, 50:151
- spectral analysis, dipole analysis, 50:151
- spectral analysis, electroencephalography, 50:151
- temporal lobes, Alzheimer's disease, 50:163
- temporal lobes, electroencephalography, 50:163
- temporal lobes, motor performance, 50:163
- unipolar depression, regional cerebral blood flow, 50:233
- unipolar depression, single photon emission computed tomography, 50:233
- ventricle-brain ratio, alcohol dependence, 50:257
- ventricle-brain ratio, cerebrospinal fluid volume, 50:257
- ventricle-brain ratio, computed tomography, 50:257
- ventricle-brain ratio, magnetic resonance imaging, 50:257
- Alcohol dependence**
- aging, cerebrospinal fluid volume, 50:257
- aging, computed tomography, 50:257
- aging, magnetic resonance imaging, 50:257
- aging, ventricle-brain ratio, 50:257
- benzodiazepine receptor, flumazenil, 50:1
- benzodiazepine receptor, magnetic resonance imaging, 50:1
- benzodiazepine receptor, positron emission tomography, 50:1
- cerebrospinal fluid volume, aging, 50:257
- cerebrospinal fluid volume, computed tomography, 50:257
- cerebrospinal fluid volume, magnetic resonance imaging, 50:257
- cerebrospinal fluid volume, ventricle-brain ratio, 50:257
- computed tomography, aging, 50:257
- computed tomography, cerebrospinal fluid volume, 50:257

**Alcohol dependence continued**

- computed tomography, image segmentation, 50:101
- computed tomography, Korsakoff syndrome, 50:101
- computed tomography, magnetic resonance imaging, 50:257
- computed tomography, thresholding methods, 50:101
- computed tomography, ventricle-brain ratio, 50:257
- flumazenil, benzodiazepine receptor, 50:1
- flumazenil, magnetic resonance imaging, 50:1
- flumazenil, positron emission tomography, 50:1
- image segmentation, computed tomography, 50:101
- image segmentation, Korsakoff syndrome, 50:101
- image segmentation, thresholding methods, 50:101
- Korsakoff syndrome, computed tomography, 50:101
- Korsakoff syndrome, image segmentation, 50:101
- Korsakoff syndrome, thresholding methods, 50:101
- magnetic resonance imaging, aging, 50:257
- magnetic resonance imaging, benzodiazepine receptor, 50:1
- magnetic resonance imaging, cerebrospinal fluid volume, 50:257
- magnetic resonance imaging, computed tomography, 50:257
- magnetic resonance imaging, flumazenil, 50:1
- magnetic resonance imaging, positron emission tomography, 50:1
- magnetic resonance imaging, ventricle-brain ratio, 50:1, 50:257
- positron emission tomography, benzodiazepine receptor, 50:1
- positron emission tomography, flumazenil, 50:1
- positron emission tomography, magnetic resonance imaging, 50:1
- thresholding methods, computed tomography, 50:101
- thresholding methods, image segmentation, 50:101
- thresholding methods, Korsakoff syndrome, 50:101
- ventricle-brain ratio, aging, 50:257
- ventricle-brain ratio, cerebrospinal fluid volume, 50:257
- ventricle-brain ratio, computed tomography, 50:257
- ventricle-brain ratio, magnetic resonance imaging, 50:1, 50:257
- Alzheimer's disease**
- aging, dipole analysis, 50:151
- aging, electroencephalography, 50:151, 50:163

**Alzheimer's disease** continued

- aging, motor performance, 50:163
- aging, music perception, 50:163
- aging, spectral analysis, 50:151
- aging, temporal lobes, 50:163
- dipole analysis, aging, 50:151
- dipole analysis, electroencephalography, 50:151
- dipole analysis, spectral analysis, 50:151
- electroencephalography, aging, 50:151, 163
- electroencephalography, dipole analysis, 50:151
- electroencephalography, motor performance, 50:163
- electroencephalography, music perception, 50:163
- electroencephalography, spectral analysis, 50:151
- electroencephalography, temporal lobes, 50:163
- motor performance, aging, 50:163
- motor performance, electroencephalography, 50:163
- motor performance, temporal lobes, 50:163
- music perception, aging, 50:163
- music perception, electroencephalography, 50:163
- spectral analysis, aging, 50:151
- spectral analysis, dipole analysis, 50:151
- spectral analysis, electroencephalography, 50:151
- temporal lobes, aging, 50:163
- temporal lobes, electroencephalography, 50:163
- temporal lobes, motor performance, 50:163

**Anxiety**

- phobia, positron emission tomography, 50:15
- phobia, regional cerebral blood flow, 50:15
- positron emission tomography, phobia, 50:15
- regional cerebral blood flow, phobia, 50:15

**Basal ganglia**

- aging, frontal lobes, 50:93
- aging, myotonic dystrophy, 50:93
- aging, positron emission tomography, 50:93
- caudate nucleus, magnetic resonance imaging, 50:89
- caudate nucleus, obsessive-compulsive disorder, 50:89
- computed tomography, neurological soft signs, 50:143
- computed tomography, obsessive-compulsive disorder, 50:143
- computed tomography, ventricle-brain ratio, 50:143
- dopamine D<sub>2</sub> receptors, methamphetamine psychosis, 50:217

**Basal ganglia** continued

- dopamine D<sub>2</sub> receptors, methylspiperone, 50:217
- dopamine D<sub>2</sub> receptors, positron emission tomography, 50:217
- dopamine D<sub>2</sub> receptors, serotonin S<sub>2</sub> receptors, 50:217
- frontal lobes, aging, 50:93
- frontal lobes, myotonic dystrophy, 50:93
- frontal lobes, positron emission tomography, 50:93
- magnetic resonance imaging, caudate nucleus, 50:89
- magnetic resonance imaging, motor learning, 50:33
- magnetic resonance imaging, obsessive-compulsive disorder, 50:89
- magnetic resonance imaging, schizophrenia, 50:33
- magnetic resonance imaging, tardive dyskinesia, 50:33
- methamphetamine psychosis, dopamine D<sub>2</sub> receptors, 50:217
- methamphetamine psychosis, methylspiperone, 50:217
- methamphetamine psychosis, positron emission tomography, 50:217
- methamphetamine psychosis, serotonin S<sub>2</sub> receptors, 50:217
- methylspiperone, dopamine D<sub>2</sub> receptors, 50:217
- methylspiperone, methamphetamine psychosis, 50:217
- methylspiperone, positron emission tomography, 50:217
- methylspiperone, serotonin S<sub>2</sub> receptors, 50:217
- motor learning, magnetic resonance imaging, 50:33
- motor learning, schizophrenia, 50:33
- motor learning, tardive dyskinesia, 50:33
- myotonic dystrophy, aging, 50:93
- myotonic dystrophy, frontal lobes, 50:93
- myotonic dystrophy, positron emission tomography, 50:93
- neurological soft signs, computed tomography, 50:143
- neurological soft signs, obsessive-compulsive disorder, 50:143
- neurological soft signs, ventricle-brain ratio, 50:143
- obsessive-compulsive disorder, caudate nucleus, 50:89
- obsessive-compulsive disorder, computed tomography, 50:143

**Basal ganglia continued**

- obsessive-compulsive disorder, magnetic resonance imaging, 50:89
- obsessive-compulsive disorder, neurological soft signs, 50:143
- obsessive-compulsive disorder, ventricle-brain ratio, 50:143
- positron emission tomography, aging, 50:93
- positron emission tomography, dopamine D<sub>2</sub> receptors, 50:217
- positron emission tomography, frontal lobes, 50:93
- positron emission tomography,
  - methamphetamine psychosis, 50:217
- positron emission tomography,
  - methylsiperone, 50:217
- positron emission tomography, myotonic dystrophy, 50:93
- positron emission tomography, serotonin S<sub>2</sub> receptors, 50:217
- schizophrenia, magnetic resonance imaging, 50:33
- schizophrenia, motor learning, 50:33
- schizophrenia, tardive dyskinesia, 50:33
- serotonin S<sub>2</sub> receptors, dopamine D<sub>2</sub> receptors, 50:217
- serotonin S<sub>2</sub> receptors, methamphetamine psychosis, 50:217
- serotonin S<sub>2</sub> receptors, methylsiperone, 50:217
- serotonin S<sub>2</sub> receptors, positron emission tomography, 50:217
- tardive dyskinesia, magnetic resonance imaging, 50:33
- tardive dyskinesia, motor learning, 50:33
- tardive dyskinesia, schizophrenia, 50:33
- ventricle-brain ratio, computed tomography, 50:143
- ventricle-brain ratio, obsessive-compulsive disorder, 50:143
- ventricle-brain ratio, neurological soft signs, 50:143

**Benzodiazepines**

- alcohol dependence, flumazenil, 50:1
- alcohol dependence, magnetic resonance imaging, 50:1
- alcohol dependence, positron emission tomography, 50:1
- flumazenil, alcohol dependence, 50:1
- flumazenil, magnetic resonance imaging, 50:1
- flumazenil, positron emission tomography, 50:1
- magnetic resonance imaging, alcohol dependence, 50:1
- magnetic resonance imaging, flumazenil, 50:1

**Benzodiazepines continued**

- magnetic resonance imaging, positron emission tomography, 50:1
- positron emission tomography, alcohol dependence, 50:1
- positron emission tomography, flumazenil, 50:1
- positron emission tomography, magnetic resonance imaging, 50:1
- Cavum septum pellucidum**
- development, magnetic resonance imaging, 50:193
- development, schizophrenia, 50:193
- magnetic resonance imaging, development, 50:193
- magnetic resonance imaging, schizophrenia, 50:193
- schizophrenia, development, 50:193
- schizophrenia, magnetic resonance imaging, 50:193
- Cerebral blood flow.** See Regional cerebral imaging, blood flow.
- Cerebrospinal fluid volume**
- aging, alcohol dependence, 50:257
- aging, computed tomography, 50:257
- aging, magnetic resonance imaging, 50:257
- aging, ventricle-brain ratio, 50:257
- alcohol dependence, aging, 50:257
- alcohol dependence, computed tomography, 50:257
- alcohol dependence, magnetic resonance imaging, 50:257
- alcohol dependence, ventricle-brain ratio, 50:257
- computed tomography, aging, 50:257
- computed tomography, alcohol dependence, 50:257
- computed tomography, magnetic resonance imaging, 50:257
- computed tomography, ventricle-brain ratio, 50:257
- magnetic resonance imaging, aging, 50:257
- magnetic resonance imaging, alcohol dependence, 50:257
- magnetic resonance imaging, computed tomography, 50:257
- magnetic resonance imaging, ventricle-brain ratio, 50:257
- ventricle-brain ratio, aging, 50:257
- ventricle-brain ratio, alcohol dependence, 50:257
- ventricle-brain ratio, computed tomography, 50:257
- ventricle-brain ratio, magnetic resonance imaging, 50:257

**Clomipramine**

clinical response prediction,  
electroencephalography, 50:25  
electroencephalography, clinical response  
prediction, 50:25

**Cognition**

electroencephalography, nootropic, 50:275  
electroencephalography, piracetam, 50:275  
electroencephalography, topographic  
analysis, 50:275  
nootropic, electroencephalography, 50:275  
nootropic, piracetam, 50:275  
nootropic, topographic analysis, 50:275  
piracetam, electroencephalography, 50:275  
piracetam, nootropic, 50:275  
piracetam, topographic analysis, 50:275  
topographic analysis, electroencephalography,  
50:275

topographic analysis, nootropic, 50:275

topographic analysis, piracetam, 50:275

**Computed tomography**

aging, alcohol dependence, 50:257  
aging, cerebrospinal fluid volume, 50:257  
aging, magnetic resonance imaging, 50:257  
aging, ventricle-brain ratio, 50:257  
alcohol dependence, aging, 50:257  
alcohol dependence, cerebrospinal fluid  
volume, 50:257  
alcohol dependence, image segmentation,  
50:101  
alcohol dependence, Korsakoff syndrome,  
50:101  
alcohol dependence, magnetic resonance  
imaging, 50:257  
alcohol dependence, thresholding methods,  
50:101  
alcohol dependence, ventricle-brain ratio,  
50:257  
basal ganglia, neurological soft signs, 50:143  
basal ganglia, obsessive-compulsive disorder,  
50:143  
basal ganglia, ventricle-brain ratio, 50:143  
cerebrospinal fluid volume, aging, 50:257  
cerebrospinal fluid volume, alcohol  
dependence, 50:257  
cerebrospinal fluid volume, magnetic  
resonance imaging, 50:257  
cerebrospinal fluid volume, ventricle-brain  
ratio, 50:257  
head size, magnetic resonance imaging, 50:121  
head size, ventricle-brain ratio, 50:121  
image segmentation, alcohol dependence,  
50:101  
image segmentation, Korsakoff syndrome,  
50:101

**Computed tomography continued**

image segmentation, thresholding methods,  
50:101  
Korsakoff syndrome, alcohol dependence,  
50:101  
Korsakoff syndrome, image segmentation,  
50:101  
Korsakoff syndrome, thresholding methods,  
50:101  
magnetic resonance imaging, aging, 50:257  
magnetic resonance imaging, alcohol  
dependence, 50:257  
magnetic resonance imaging, cerebrospinal  
fluid volume, 50:257  
magnetic resonance imaging, head size,  
50:121  
magnetic resonance imaging, ventricle-brain  
ratio, 50:121, 50:257  
neurological soft signs, basal ganglia, 50:143  
neurological soft signs, obsessive-compulsive  
disorder, 50:143  
neurological soft signs, ventricle-brain ratio,  
50:143  
obsessive-compulsive disorder, basal ganglia,  
50:143  
obsessive-compulsive disorder, neurological  
soft signs, 50:143  
obsessive-compulsive disorder, ventricle-  
brain ratio, 50:143  
thresholding methods, alcohol dependence,  
50:101  
thresholding methods, image segmentation,  
50:101  
thresholding methods, Korsakoff syndrome,  
50:101  
ventricle-brain ratio, aging, 50:257  
ventricle-brain ratio, alcohol dependence,  
50:257  
ventricle-brain ratio, basal ganglia, 50:143  
ventricle-brain ratio, cerebrospinal fluid  
volume, 50:257  
ventricle-brain ratio, head size, 50:121  
ventricle-brain ratio, magnetic resonance  
imaging, 50:121, 50:257  
ventricle-brain ratio, neurological soft signs,  
50:143  
ventricle-brain ratio, obsessive-compulsive  
disorder, 50:143  
**Dementia.** See Alzheimer's disease.  
**Depression.** See Affective disorder.  
**Development**  
cavum septum pellucidum, magnetic  
resonance imaging, 50:193  
cavum septum pellucidum, schizophrenia,  
50:193



**Development continued**

magnetic resonance imaging, cavum septum pellucidum, 50:193

magnetic resonance imaging, schizophrenia, 50:193

schizophrenia, cavum septum pellucidum, 50:193

schizophrenia, magnetic resonance imaging, 50:193

**Dopamine**

basal ganglia, methamphetamine psychosis, 50:217

basal ganglia, methylpiperone, 50:217

basal ganglia, positron emission tomography, 50:217

basal ganglia, serotonin  $S_2$  receptors, 50:217  
methamphetamine psychosis, basal ganglia, 50:217

methamphetamine psychosis, methylpiperone, 50:217

methamphetamine psychosis, positron emission tomography, 50:217

methamphetamine psychosis, serotonin  $S_2$  receptors, 50:217

methylpiperone, basal ganglia, 50:217

methylpiperone, methamphetamine psychosis, 50:217

methylpiperone, positron emission tomography, 50:217

methylpiperone, serotonin  $S_2$  receptors, 50:217

positron emission tomography, basal ganglia, 50:217

positron emission tomography, methamphetamine psychosis, 50:217

positron emission tomography, methylpiperone, 50:217

positron emission tomography, serotonin  $S_2$  receptors, 50:217

serotonin  $S_2$  receptors, basal ganglia, 50:217

serotonin  $S_2$  receptors, methamphetamine psychosis, 50:217

serotonin  $S_2$  receptors, methylpiperone, 50:217

serotonin  $S_2$  receptors, positron emission tomography, 50:217

**Electroencephalography**

aging, Alzheimer's disease, 50:151, 50:163

aging, dipole analysis, 50:151

aging, motor performance, 50:163

aging, music perception, 50:163

aging, spectral analysis, 50:151

aging, temporal lobes, 50:163

Alzheimer's disease, aging, 50:151, 50:163

Alzheimer's disease, dipole analysis, 50:151

**Electroencephalography continued**

Alzheimer's disease, motor performance, 50:163

Alzheimer's disease, music perception, 50:163

Alzheimer's disease, spectral analysis, 50:151

Alzheimer's disease, temporal lobes, 50:163

clinical response prediction, fluoxetine, 50:25

clinical response prediction, obsessive-compulsive disorder, 50:25

clinical response prediction, serotonin reuptake inhibitors, 50:25

cognition, nootropic, 50:275

cognition, piracetam, 50:275

cognition, topographic analysis, 50:275

dipole analysis, aging, 50:151

dipole analysis, Alzheimer's disease, 50:151

dipole analysis, spectral analysis, 50:151  
fluoxetine, clinical response prediction, 50:25

fluoxetine, obsessive-compulsive disorder, 50:25

motor performance, aging, 50:163

motor performance, Alzheimer's disease, 50:163

motor performance, temporal lobes, 50:163

music perception, aging, 50:163

music perception, Alzheimer's disease, 50:163

nootropic, cognition, 50:275

nootropic, topographic analysis, 50:275

obsessive-compulsive disorder, clinical response prediction, 50:25

obsessive-compulsive disorder, fluoxetine, 50:25

obsessive-compulsive disorder, serotonin reuptake inhibitors, 50:25

piracetam, cognition, 50:275

piracetam, topographic analysis, 50:275

serotonin reuptake inhibitors, clinical response prediction, 50:25

serotonin reuptake inhibitors, obsessive-compulsive disorder, 50:25

space-oriented segmentation, topographic analysis, 50:275

spectral analysis, aging, 50:151

spectral analysis, Alzheimer's disease, 50:151

spectral analysis, dipole analysis, 50:151

temporal lobes, aging, 50:163

temporal lobes, Alzheimer's disease, 50:163

temporal lobes, motor performance, 50:163

topographic analysis, cognition, 50:275

topographic analysis, nootropic, 50:275

topographic analysis, piracetam, 50:275

topographic analysis, space-oriented segmentation, 50:275



**Flumazenil**

- alcohol dependence, benzodiazepine receptor, 50:1
- alcohol dependence, magnetic resonance imaging, 50:1
- alcohol dependence, positron emission tomography, 50:1
- benzodiazepine receptor, alcohol dependence, 50:1
- benzodiazepine receptor, magnetic resonance imaging, 50:1
- benzodiazepine receptor, positron emission tomography, 50:1
- magnetic resonance imaging, alcohol dependence, 50:1
- magnetic resonance imaging, benzodiazepine receptor, 50:1
- magnetic resonance imaging, positron emission tomography, 50:1
- positron emission tomography, alcohol dependence, 50:1
- positron emission tomography, benzodiazepine receptor, 50:1
- positron emission tomography, magnetic resonance imaging, 50:1

**Fluoxetine**

- clinical response prediction, electroencephalography, 50:25
- clinical response prediction, obsessive-compulsive disorder, 50:25
- electroencephalography, clinical response prediction, 50:25
- electroencephalography, obsessive-compulsive disorder, 50:25
- obsessive-compulsive disorder, clinical response prediction, 50:25
- obsessive-compulsive disorder, electroencephalography, 50:25

**Fluvoxamine**

- clinical response prediction, electroencephalography, 50:25
- electroencephalography, clinical response prediction, 50:25

**Frontal lobes**

- affective disorder, regional cerebral blood flow, 50:77
- affective disorder, single photon emission computed tomography, 50:77
- aging, basal ganglia, 50:93
- aging, myotonic dystrophy, 50:93
- aging, positron emission tomography, 50:93
- basal ganglia, aging, 50:93
- basal ganglia, myotonic dystrophy, 50:93
- basal ganglia, positron emission tomography, 50:93

**Frontal lobes continued**

- catatonia, iodoamphetamine, 50:203
- catatonia, parietal lobes, 50:203
- catatonia, regional cerebral blood flow, 50:203
- catatonia, schizophrenia, 50:203
- catatonia, single photon emission computed tomography, 50:203
- iodoamphetamine, catatonia, 50:203
- iodoamphetamine, parietal lobes, 50:203
- iodoamphetamine, regional cerebral blood flow, 50:203
- iodoamphetamine, schizophrenia, 50:203
- iodoamphetamine, single photon emission computed tomography, 50:203
- myotonic dystrophy, aging, 50:93
- myotonic dystrophy, basal ganglia, 50:93
- myotonic dystrophy, positron emission tomography, 50:93
- parietal lobes, catatonia, 50:203
- parietal lobes, iodoamphetamine, 50:203
- parietal lobes, regional cerebral blood flow, 50:203
- parietal lobes, schizophrenia, 50:203
- parietal lobes, single photon emission computed tomography, 50:203
- positron emission tomography, aging, 50:93
- positron emission tomography, basal ganglia, 50:93
- positron emission tomography, myotonic dystrophy, 50:93
- regional cerebral blood flow, affective disorder, 50:77
- regional cerebral blood flow, catatonia, 50:203
- regional cerebral blood flow, iodoamphetamine, 50:203
- regional cerebral blood flow, parietal lobes, 50:203
- regional cerebral blood flow, schizophrenia, 50:203
- regional cerebral blood flow, single photon emission computed tomography, 50:77
- regional cerebral blood flow, single photon emission computed tomography, 50:177
- regional cerebral blood flow, single photon emission computed tomography, 50:203
- regional cerebral blood flow, task difficulty, 50:177
- regional cerebral blood flow, unipolar depression, 50:77
- regional cerebral blood flow, Wisconsin Card Sorting Test, 50:177
- schizophrenia, catatonia, 50:203
- schizophrenia, iodoamphetamine, 50:203

**Frontal lobes continued**

- schizophrenia, parietal lobes, 50:203
- schizophrenia, regional cerebral blood flow, 50:203
- schizophrenia, single photon emission computed tomography, 50:203
- single photon emission computed tomography, affective disorder, 50:77
- single photon emission computed tomography, catatonia, 50:203
- single photon emission computed tomography, iodoamphetamine, 50:203
- single photon emission computed tomography, parietal lobes, 50:203
- single photon emission computed tomography, schizophrenia, 50:203
- single photon emission computed tomography, task difficulty, 50:177
- single photon emission computed tomography, unipolar depression, 50:77
- single photon emission computed tomography, Wisconsin Card Sorting Test, 50:177
- task difficulty, regional cerebral blood flow, 50:177
- task difficulty, single photon emission computed tomography, 50:177
- task difficulty, Wisconsin Card Sorting Test, 50:177
- unipolar depression, regional cerebral blood flow, 50:77
- unipolar depression, single photon emission computed tomography, 50:77
- Wisconsin Card Sorting Test, regional cerebral blood flow, 50:177
- Wisconsin Card Sorting Test, single photon emission computed tomography, 50:177
- Wisconsin Card Sorting Test, task difficulty, 50:177

**Image reconstruction**

- magnetic resonance imaging, region of interest, 50:57
- magnetic resonance imaging, single photon emission computed tomography, 50:57
- region of interest, magnetic resonance imaging, 50:57
- region of interest, single photon emission computed tomography, 50:57
- single photon emission computed tomography, magnetic resonance imaging, 50:57
- single photon emission computed tomography, region of interest, 50:57

**Image segmentation**

- alcohol dependence, computed tomography, 50:101

**Image segmentation continued**

- alcohol dependence, Korsakoff syndrome, 50:101
- alcohol dependence, thresholding methods, 50:101
- computed tomography, alcohol dependence, 50:101
- computed tomography, Korsakoff syndrome, 50:101
- computed tomography, thresholding methods, 50:101
- Korsakoff syndrome, alcohol dependence, 50:101
- Korsakoff syndrome, computed tomography, 50:101
- Korsakoff syndrome, thresholding methods, 50:101
- thresholding methods, alcohol dependence, 50:101
- thresholding methods, computed tomography, 50:101
- thresholding methods, Korsakoff syndrome, 50:101
- Iodoamphetamine**
- catatonia, frontal lobes, 50:203
- catatonia, parietal lobes, 50:203
- catatonia, regional cerebral blood flow, 50:203
- catatonia, schizophrenia, 50:203
- catatonia, single photon emission computed tomography, 50:203
- frontal lobes, catatonia, 50:203
- frontal lobes, parietal lobes, 50:203
- frontal lobes, regional cerebral blood flow, 50:203
- frontal lobes, schizophrenia, 50:203
- frontal lobes, single photon emission computed tomography, 50:203
- parietal lobes, catatonia, 50:203
- parietal lobes, frontal lobes, 50:203
- parietal lobes, regional cerebral blood flow, 50:203
- parietal lobes, schizophrenia, 50:203
- parietal lobes, single photon emission computed tomography, 50:203
- regional cerebral blood flow, catatonia, 50:203
- regional cerebral blood flow, frontal lobes, 50:203
- regional cerebral blood flow, parietal lobes, 50:203
- regional cerebral blood flow, schizophrenia, 50:203
- schizophrenia, catatonia, 50:203
- schizophrenia, frontal lobes, 50:203

**Iodoamphetamine** continued

- schizophrenia, parietal lobes, 50:203
- schizophrenia, regional cerebral blood flow, 50:203
- schizophrenia, single photon emission computed tomography, 50:203
- single photon emission computed tomography, catatonia, 50:203
- single photon emission computed tomography, frontal lobes, 50:203
- single photon emission computed tomography, parietal lobes, 50:203
- single photon emission computed tomography, schizophrenia, 50:203

**Korsakoff syndrome**

- alcohol dependence, computed tomography, 50:101
- alcohol dependence, image segmentation, 50:101
- alcohol dependence, thresholding methods, 50:101
- computed tomography, alcohol dependence, 50:101
- computed tomography, image segmentation, 50:101
- computed tomography, thresholding methods, 50:101
- image segmentation, alcohol dependence, 50:101
- image segmentation, computed tomography, 50:101
- image segmentation, thresholding methods, 50:101
- thresholding methods, alcohol dependence, 50:101
- thresholding methods, computed tomography, 50:101
- thresholding methods, image segmentation, 50:101

**Lithium**

- magnetic resonance spectroscopy, pharmacokinetics, 50:67
- pharmacokinetics, magnetic resonance spectroscopy, 50:67

**Magnetic resonance imaging**

- aging, alcohol dependence, 50:257
- aging, cerebrospinal fluid volume, 50:257
- aging, computed tomography, 50:257
- aging, ventricle-brain ratio, 50:257
- alcohol dependence, aging, 50:257
- alcohol dependence, benzodiazepine receptor, 50:1
- alcohol dependence, cerebrospinal fluid volume, 50:257

**Magnetic resonance imaging** continued

- alcohol dependence, computed tomography, 50:257
- alcohol dependence, flumazenil, 50:1
- alcohol dependence, positron emission tomography, 50:1
- alcohol dependence, ventricle-brain ratio, 50:1, 50:257
- basal ganglia, motor learning, 50:33
- basal ganglia, obsessive-compulsive disorder, 50:89
- basal ganglia, schizophrenia, 50:33
- basal ganglia, tardive dyskinesia, 50:33
- benzodiazepine receptor, alcohol dependence, 50:1
- benzodiazepine receptor, flumazenil, 50:1
- benzodiazepine receptor, positron emission tomography, 50:1
- caudate nucleus, obsessive-compulsive disorder, 50:89
- cavum septum pellucidum, development, 50:193
- cavum septum pellucidum, schizophrenia, 50:193
- cerebrospinal fluid volume, aging, 50:257
- cerebrospinal fluid volume, alcohol dependence, 50:257
- cerebrospinal fluid volume, computed tomography, 50:257
- cerebrospinal fluid volume, ventricle-brain ratio, 50:257
- computed tomography, aging, 50:257
- computed tomography, alcohol dependence, 50:257
- computed tomography, cerebrospinal fluid volume, 50:257
- computed tomography, head size, 50:121
- computed tomography, ventricle-brain ratio, 50:121, 50:257
- development, cavum septum pellucidum, 50:193
- development, schizophrenia, 50:193
- flumazenil, alcohol dependence, 50:1
- flumazenil, benzodiazepine receptor, 50:1
- flumazenil, positron emission tomography, 50:1
- head size, computed tomography, 50:121
- head size correction, reliability, 50:203
- head size, schizophrenia, 50:121
- head size, ventricle-brain ratio, 50:121
- image registration, region of interest, 50:57
- image registration, single photon emission computed tomography, 50:57
- memory, schizophrenia, 50:45
- memory, temporal lobe area, 50:45

**Magnetic resonance imaging** continued  
 motor learning, basal ganglia, 50:33  
 motor learning, schizophrenia, 50:33  
 motor learning, tardive dyskinesia, 50:33  
 obsessive-compulsive disorder, basal ganglia, 50:89  
 obsessive-compulsive disorder, caudate nucleus, 50:89  
 positron emission tomography, alcohol dependence, 50:1  
 positron emission tomography, benzodiazepine receptor, 50:1  
 positron emission tomography, flumazenil, 50:1  
 region of interest, image registration, 50:57  
 region of interest, single photon emission computed tomography, 50:57  
 reliability, head size correction, 50:203  
 schizophrenia, basal ganglia, 50:33  
 schizophrenia, cavum septum pellucidum, 50:193  
 schizophrenia, development, 50:193  
 schizophrenia, head size, 50:121  
 schizophrenia, memory, 50:45  
 schizophrenia, motor learning, 50:33  
 schizophrenia, tardive dyskinesia, 50:33  
 schizophrenia, temporal lobe area, 50:45  
 single photon emission computed tomography, image registration, 50:57  
 single photon emission computed tomography, region of interest, 50:57  
 tardive dyskinesia, basal ganglia, 50:33  
 tardive dyskinesia, motor learning, 50:33  
 tardive dyskinesia, schizophrenia, 50:33  
 temporal lobe area, memory, 50:45  
 temporal lobe area, schizophrenia, 50:45  
 ventricle-brain ratio, aging, 50:257  
 ventricle-brain ratio, alcohol dependence, 50:1, 50:257  
 ventricle-brain ratio, cerebrospinal fluid volume, 50:257  
 ventricle-brain ratio, computed tomography, 50:121, 50:257  
 ventricle-brain ratio, head size, 50:121  
**Magnetic resonance spectroscopy**  
 lithium, pharmacokinetics, 50:67  
 pharmacokinetics, lithium, 50:67  
**Memory**  
 magnetic resonance imaging, schizophrenia, 50:45  
 magnetic resonance imaging, temporal lobe area, 50:45  
 schizophrenia, magnetic resonance imaging, 50:45  
 schizophrenia, temporal lobe area, 50:45

**Magnetic resonance spectroscopy** continued  
 temporal lobe area, magnetic resonance imaging, 50:45  
 temporal lobe area, schizophrenia, 50:45  
**Methamphetamine**  
 basal ganglia, dopamine D<sub>2</sub> receptors, 50:217  
 basal ganglia, methylspiperone, 50:217  
 basal ganglia, positron emission tomography, 50:217  
 basal ganglia, serotonin S<sub>2</sub> receptors, 50:217  
 dopamine D<sub>2</sub> receptors, basal ganglia, 50:217  
 dopamine D<sub>2</sub> receptors, methylspiperone, 50:217  
 dopamine D<sub>2</sub> receptors, positron emission tomography, 50:217  
 dopamine D<sub>2</sub> receptors, serotonin S<sub>2</sub> receptors, 50:217  
 methylspiperone, basal ganglia, 50:217  
 methylspiperone, dopamine D<sub>2</sub> receptors, 50:217  
 methylspiperone, positron emission tomography, 50:217  
 methylspiperone, serotonin S<sub>2</sub> receptors, 50:217  
 positron emission tomography, basal ganglia, 50:217  
 positron emission tomography, dopamine D<sub>2</sub> receptors, 50:217  
 positron emission tomography, methylspiperone, 50:217  
 positron emission tomography, serotonin S<sub>2</sub> receptors, 50:217  
 serotonin S<sub>2</sub> receptors, basal ganglia, 50:217  
 serotonin S<sub>2</sub> receptors, dopamine D<sub>2</sub> receptors, 50:217  
 serotonin S<sub>2</sub> receptors, methylspiperone, 50:217  
 serotonin S<sub>2</sub> receptors, positron emission tomography, 50:217  
**Methylspiperone**  
 basal ganglia, dopamine D<sub>2</sub> receptors, 50:217  
 basal ganglia, methamphetamine psychosis, 50:217  
 basal ganglia, positron emission tomography, 50:217  
 basal ganglia, serotonin S<sub>2</sub> receptors, 50:217  
 dopamine D<sub>2</sub> receptors, basal ganglia, 50:217  
 dopamine D<sub>2</sub> receptors, methamphetamine psychosis, 50:217  
 dopamine D<sub>2</sub> receptors, positron emission tomography, 50:217  
 dopamine D<sub>2</sub> receptors, serotonin S<sub>2</sub> receptors, 50:217  
 methamphetamine psychosis, basal ganglia, 50:217  
 methamphetamine psychosis, dopamine D<sub>2</sub> receptors, 50:217

**Methylspiperone continued**

methamphetamine psychosis, positron emission tomography, 50:217  
 methamphetamine psychosis, serotonin S<sub>2</sub> receptors, 50:217  
 positron emission tomography, basal ganglia, 50:217  
 positron emission tomography, dopamine D<sub>2</sub> receptors, 50:217  
 positron emission tomography, methamphetamine psychosis, 50:217  
 positron emission tomography, serotonin S<sub>2</sub> receptors, 50:217  
 serotonin S<sub>2</sub> receptors, basal ganglia, 50:217  
 serotonin S<sub>2</sub> receptors, dopamine D<sub>2</sub> receptors, 50:217  
 serotonin S<sub>2</sub> receptors, methamphetamine psychosis, 50:217  
 serotonin S<sub>2</sub> receptors, positron emission tomography, 50:217

**Motor performance**

aging, Alzheimer's disease, 50:163  
 aging, electroencephalography, 50:163  
 aging, temporal lobes, 50:163  
 Alzheimer's disease, aging, 50:163  
 Alzheimer's disease, electroencephalography, 50:163  
 Alzheimer's disease, temporal lobes, 50:163  
 electroencephalography, aging, 50:163  
 electroencephalography, Alzheimer's disease, 50:163  
 electroencephalography, temporal lobes, 50:163  
 temporal lobes, aging, 50:163  
 temporal lobes, Alzheimer's disease, 50:163  
 temporal lobes, electroencephalography, 50:163

**Myotonic dystrophy**

aging, basal ganglia, 50:93  
 aging, frontal lobes, 50:93  
 aging, positron emission tomography, 50:93  
 basal ganglia, aging, 50:93  
 basal ganglia, frontal lobes, 50:93  
 basal ganglia, positron emission tomography, 50:93  
 frontal lobes, aging, 50:93  
 frontal lobes, basal ganglia, 50:93  
 frontal lobes, positron emission tomography, 50:93  
 positron emission tomography, aging, 50:93  
 positron emission tomography, basal ganglia, 50:93  
 positron emission tomography, frontal lobes, 50:93

**Neurological soft signs**

basal ganglia, computed tomography, 50:143

**Neurological soft signs continued**

basal ganglia, obsessive-compulsive disorder, 50:143  
 basal ganglia, ventricle-brain ratio, 50:143  
 computed tomography, basal ganglia, 50:143  
 computed tomography, obsessive-compulsive disorder, 50:143  
 computed tomography, ventricle-brain ratio, 50:143  
 obsessive-compulsive disorder, basal ganglia, 50:143  
 obsessive-compulsive disorder, computed tomography, 50:143  
 obsessive-compulsive disorder, ventricle-brain ratio, 50:143  
 ventricle-brain ratio, basal ganglia, 50:143  
 ventricle-brain ratio, obsessive-compulsive disorder, 50:143

**Nootropics**

cognition, electroencephalography, 50:275  
 cognition, piracetam, 50:275  
 cognition, topographic analysis, 50:275  
 electroencephalography, cognition, 50:275  
 electroencephalography, piracetam, 50:275  
 electroencephalography, topographic analysis, 50:275  
 piracetam, cognition, 50:275  
 piracetam, electroencephalography, 50:275  
 piracetam, topographic analysis, 50:275  
 topographic analysis, cognition, 50:275  
 topographic analysis, electroencephalography, 50:275

topographic analysis, piracetam, 50:275

**Obsessive-compulsive disorder**

basal ganglia, computed tomography, 50:143  
 basal ganglia, magnetic resonance imaging, 50:89  
 basal ganglia, neurological soft signs, 50:143  
 basal ganglia, ventricle-brain ratio, 50:143  
 caudate nucleus, magnetic resonance imaging, 50:89  
 clinical response prediction, electroencephalography, 50:25  
 clinical response prediction, fluoxetine, 50:25  
 clinical response prediction, serotonin reuptake inhibitors, 50:25  
 computed tomography, basal ganglia, 50:143  
 computed tomography, neurological soft signs, 50:143  
 computed tomography, ventricle-brain ratio, 50:143  
 electroencephalography, clinical response prediction, 50:25  
 electroencephalography, fluoxetine, 50:25

**Obsessive-compulsive disorder** continued  
 electroencephalography, serotonin reuptake inhibitors, 50:25  
 fluoxetine, clinical response prediction, 50:25  
 fluoxetine, electroencephalography, 50:25  
 magnetic resonance imaging, basal ganglia, 50:89  
 magnetic resonance imaging, caudate nucleus, 50:89  
 neurological soft signs, basal ganglia, 50:143  
 neurological soft signs, computed tomography, 50:143  
 neurological soft signs, ventricle-brain ratio, 50:143  
 serotonin reuptake inhibitors, clinical response prediction, 50:25  
 serotonin reuptake inhibitors, electroencephalography, 50:25  
 ventricle-brain ratio, basal ganglia, 50:143  
 ventricle-brain ratio, neurological soft signs, 50:143

**Parietal lobes**  
 catatonia, frontal lobes, 50:203  
 catatonia, iodoamphetamine, 50:203  
 catatonia, regional cerebral blood flow, 50:203  
 catatonia, schizophrenia, 50:203  
 catatonia, single photon emission computed tomography, 50:203  
 frontal lobes, catatonia, 50:203  
 frontal lobes, iodoamphetamine, 50:203  
 frontal lobes, regional cerebral blood flow, 50:203  
 frontal lobes, schizophrenia, 50:203  
 frontal lobes, single photon emission computed tomography, 50:203  
 iodoamphetamine, catatonia, 50:203  
 iodoamphetamine, frontal lobes, 50:203  
 iodoamphetamine, regional cerebral blood flow, 50:203  
 iodoamphetamine, schizophrenia, 50:203  
 iodoamphetamine, single photon emission computed tomography, 50:203  
 regional cerebral blood flow, catatonia, 50:203  
 regional cerebral blood flow, frontal lobes, 50:203  
 regional cerebral blood flow, iodoamphetamine, 50:203  
 regional cerebral blood flow, schizophrenia, 50:203  
 schizophrenia, catatonia, 50:203  
 schizophrenia, frontal lobes, 50:203  
 schizophrenia, iodoamphetamine, 50:203

**Parietal lobes** continued  
 schizophrenia, regional cerebral blood flow, 50:203  
 schizophrenia, single photon emission computed tomography, 50:203  
 single photon emission computed tomography, catatonia, 50:203  
 single photon emission computed tomography, frontal lobes, 50:203  
 single photon emission computed tomography, iodoamphetamine, 50:203  
 single photon emission computed tomography, schizophrenia, 50:203

**Pharmacokinetics**  
 lithium, magnetic resonance spectroscopy, 50:67  
 magnetic resonance spectroscopy, lithium, 50:67

**Phobia**  
 anxiety, positron emission tomography, 50:15  
 anxiety, regional cerebral blood flow, 50:15  
 positron emission tomography, anxiety, 50:15  
 positron emission tomography, regional cerebral blood flow, 50:15  
 positron emission tomography, snake anxiety, 50:15  
 regional cerebral blood flow, anxiety, 50:15  
 regional cerebral blood flow, positron emission tomography, 50:15  
 snake anxiety, positron emission tomography, 50:15

**Piracetam**  
 cognition, electroencephalography, 50:275  
 cognition, topographic analysis, 50:275  
 electroencephalography, cognition, 50:275  
 electroencephalography, topographic analysis, 50:275  
 topographic analysis, cognition, 50:275  
 topographic analysis, electroencephalography, 50:275

**Positron emission tomography**  
 aging, basal ganglia, 50:93  
 aging, frontal lobes, 50:93  
 aging, myotonic dystrophy, 50:93  
 alcohol dependence, benzodiazepine receptor, 50:1  
 alcohol dependence, flumazenil, 50:1  
 alcohol dependence, magnetic resonance imaging, 50:1  
 anxiety, phobia, 50:15  
 anxiety, regional cerebral blood flow, 50:15  
 basal ganglia, aging, 50:93  
 basal ganglia, dopamine D<sub>2</sub> receptor, 50:217  
 basal ganglia, frontal lobes, 50:93



**Positron emission tomography continued**

basal ganglia, methamphetamine psychosis, 50:217  
 basal ganglia, methylspiperone, 50:217  
 basal ganglia, myotonic dystrophy, 50:93  
 basal ganglia, serotonin  $S_2$  receptors, 50:217  
 benzodiazepine receptor, alcohol dependence, 50:1  
 benzodiazepine receptor, flumazenil, 50:1  
 benzodiazepine receptor, magnetic resonance imaging, 50:1  
 dopamine  $D_2$  receptors, basal ganglia, 50:217  
 dopamine  $D_2$  receptors, methamphetamine psychosis, 50:217  
 dopamine  $D_2$  receptors, methylspiperone, 50:217  
 dopamine  $D_2$  receptors, serotonin  $S_2$  receptors, 50:217  
 flumazenil, alcohol dependence, 50:1  
 flumazenil, benzodiazepine receptor, 50:1  
 flumazenil, magnetic resonance imaging, 50:1  
 frontal lobes, aging, 50:93  
 frontal lobes, basal ganglia, 50:93  
 frontal lobes, myotonic dystrophy, 50:93  
 magnetic resonance imaging, alcohol dependence, 50:1  
 magnetic resonance imaging, benzodiazepine receptor, 50:1  
 magnetic resonance imaging, flumazenil, 50:1  
 methamphetamine psychosis, basal ganglia, 50:217  
 methamphetamine psychosis, dopamine  $D_2$  receptors, 50:217  
 methamphetamine psychosis, methylspiperone, 50:217  
 methamphetamine psychosis, serotonin  $S_2$  receptors, 50:217  
 methylspiperone, basal ganglia, 50:217  
 methylspiperone, dopamine  $D_2$  receptors, 50:217  
 methylspiperone, methamphetamine psychosis, 50:217  
 methylspiperone, serotonin  $S_2$  receptors, 50:217  
 myotonic dystrophy, aging, 50:93  
 myotonic dystrophy, basal ganglia, 50:93  
 myotonic dystrophy, frontal lobes, 50:93  
 phobia, anxiety, 50:15  
 phobia, regional cerebral blood flow, 50:15  
 regional cerebral blood flow, anxiety, 50:15  
 regional cerebral blood flow, phobia, 50:15  
 serotonin  $S_2$  receptors, basal ganglia, 50:217  
 serotonin  $S_2$  receptors, dopamine  $D_2$  receptors, 50:217

**Positron emission tomography continued**

serotonin  $S_2$  receptors, methamphetamine psychosis, 50:217  
 serotonin  $S_2$  receptors, methylspiperone, 50:217  
**Pursuit rotor task**  
 motor learning, schizophrenia, 50:33  
 schizophrenia, motor learning, 50:33  
**Regional cerebral blood flow**  
 affective disorder, aging, 50:233  
 affective disorder, frontal lobes, 50:77  
 affective disorder, single photon emission computed tomography, 50:77, 50:233  
 aging, affective disorder, 50:233  
 aging, single photon emission computed tomography, 50:233  
 aging, unipolar depression, 50:233  
 anxiety, positron emission tomography, 50:15  
 catatonia, frontal lobes, 50:203  
 catatonia, iodoamphetamine, 50:203  
 catatonia, parietal lobes, 50:203  
 catatonia, schizophrenia, 50:203  
 catatonia, single photon emission computed tomography, 50:203  
 frontal lobes, affective disorder, 50:77  
 frontal lobes, catatonia, 50:203  
 frontal lobes, iodoamphetamine, 50:203  
 frontal lobes, parietal lobes, 50:203  
 frontal lobes, schizophrenia, 50:203  
 frontal lobes, single photon emission computed tomography, 50:77, 50:177, 50:203  
 frontal lobes, task difficulty, 50:177  
 frontal lobes, unipolar depression, 50:77  
 frontal lobes, Wisconsin Card Sorting Test, 50:177  
 iodoamphetamine, catatonia, 50:203  
 iodoamphetamine, frontal lobes, 50:203  
 iodoamphetamine, parietal lobes, 50:203  
 iodoamphetamine, schizophrenia, 50:203  
 iodoamphetamine, single photon emission computed tomography, 50:203  
 parietal lobes, catatonia, 50:203  
 parietal lobes, frontal lobes, 50:203  
 parietal lobes, iodoamphetamine, 50:203  
 parietal lobes, schizophrenia, 50:203  
 parietal lobes, single photon emission computed tomography, 50:203  
 phobia, positron emission tomography, 50:15  
 positron emission tomography, anxiety, 50:15  
 positron emission tomography, phobia, 50:15  
 schizophrenia, catatonia, 50:203  
 schizophrenia, frontal lobes, 50:203  
 schizophrenia, iodoamphetamine, 50:203



**Regional cerebral blood flow**

- schizophrenia, parietal lobes, 50:203
- schizophrenia, single photon emission computed tomography, 50:203
- single photon emission computed tomography, affective disorder, 50:77, 50:233
- single photon emission computed tomography, aging, 50:233
- single photon emission computed tomography, catatonia, 50:233
- single photon emission computed tomography, frontal lobes, 50:77, 50:177, 50:233
- single photon emission computed tomography, iodoamphetamine, 50:233
- single photon emission computed tomography, parietal lobes, 50:203
- single photon emission computed tomography, schizophrenia, 50:203
- single photon emission computed tomography, task difficulty, 50:177
- single photon emission computed tomography, unipolar depression, 50:77, 50:233
- single photon emission computed tomography, Wisconsin Card Sorting Test, 50:177
- task difficulty, frontal lobes, 50:177
- task difficulty, single photon emission computed tomography, 50:177
- task difficulty, Wisconsin Card Sorting Test, 50:177
- unipolar depression, aging, 50:233
- unipolar depression, frontal lobes, 50:77
- unipolar depression, single photon emission computed tomography, 50:77, 50:233
- Wisconsin Card Sorting Test, frontal lobes, 50:177
- Wisconsin Card Sorting Test, single photon emission computed tomography, 50:177
- Wisconsin Card Sorting Test, task difficulty, 50:177

**Schizophrenia**

- basal ganglia, magnetic resonance imaging, 50:33
- basal ganglia, motor learning, 50:33
- basal ganglia, tardive dyskinesia, 50:33
- catatonia, frontal lobes, 50:203
- catatonia, iodoamphetamine, 50:203
- catatonia, parietal lobes, 50:203
- catatonia, regional cerebral blood flow, 50:203
- catatonia, single photon emission computed tomography, 50:203
- cavum septum pellucidum, development, 50:193
- cavum septum pellucidum, magnetic resonance imaging, 50:193

**Schizophrenia continued**

- development, cavum septum pellucidum, 50:193
- development, magnetic resonance imaging, 50:193
- frontal lobes, catatonia, 50:203
- frontal lobes, iodoamphetamine, 50:203
- frontal lobes, parietal lobes, 50:203
- frontal lobes, regional cerebral blood flow, 50:203
- frontal lobes, single photon emission computed tomography, 50:203
- head size, magnetic resonance imaging, 50:121
- iodoamphetamine, catatonia, 50:203
- iodoamphetamine, frontal lobes, 50:203
- iodoamphetamine, parietal lobes, 50:203
- iodoamphetamine, regional cerebral blood flow, 50:203
- iodoamphetamine, single photon emission computed tomography, 50:203
- magnetic resonance imaging, basal ganglia, 50:33
- magnetic resonance imaging, cavum septum pellucidum, 50:193
- magnetic resonance imaging, development, 50:193
- magnetic resonance imaging, head size, 50:121
- magnetic resonance imaging, memory, 50:45
- magnetic resonance imaging, motor learning, 50:33
- magnetic resonance imaging, tardive dyskinesia, 50:33
- magnetic resonance imaging, temporal lobe area, 50:45
- memory, magnetic resonance imaging, 50:45
- memory, temporal lobe area, 50:45
- motor learning, basal ganglia, 50:33
- motor learning, magnetic resonance imaging, 50:33
- motor learning, tardive dyskinesia, 50:33
- parietal lobes, catatonia, 50:203
- parietal lobes, frontal lobes, 50:203
- parietal lobes, iodoamphetamine, 50:203
- parietal lobes, regional cerebral blood flow, 50:203
- parietal lobes, single photon emission computed tomography, 50:203
- regional cerebral blood flow, catatonia, 50:203
- regional cerebral blood flow, frontal lobes, 50:203
- regional cerebral blood flow, iodoamphetamine, 50:203

**Schizophrenia** continued

- regional cerebral blood flow, parietal lobes, 50:203
- single photon emission computed tomography, catatonia, 50:203
- single photon emission computed tomography, frontal lobes, 50:203
- single photon emission computed tomography, iodoamphetamine, 50:203
- single photon emission computed tomography, parietal lobes, 50:203
- tardive dyskinesia, basal ganglia, 50:33
- tardive dyskinesia, magnetic resonance imaging, 50:33
- tardive dyskinesia, motor learning, 50:33
- temporal lobe area, magnetic resonance imaging, 50:45
- temporal lobe area, memory, 50:45

**Serotonin**

- basal ganglia, dopamine D<sub>2</sub> receptors, 50:217
- basal ganglia, methamphetamine psychosis, 50:217
- basal ganglia, methylspiperone, 50:217
- basal ganglia, positron emission tomography, 50:217
- clinical response prediction, electroencephalography, 50:25
- clinical response prediction, obsessive-compulsive disorder, 50:25
- dopamine D<sub>2</sub> receptors, basal ganglia, 50:217
- dopamine D<sub>2</sub> receptors, methamphetamine psychosis, 50:217
- dopamine D<sub>2</sub> receptors, methylspiperone, 50:217
- dopamine D<sub>2</sub> receptors, positron emission tomography, 50:217
- electroencephalography, clinical response prediction, 50:25
- electroencephalography, obsessive-compulsive disorder, 50:25
- methamphetamine psychosis, basal ganglia, 50:217
- methamphetamine psychosis, dopamine D<sub>2</sub> receptors, 50:217
- methamphetamine psychosis, methylspiperone, 50:217
- methamphetamine psychosis, positron emission tomography, 50:217
- methylspiperone, basal ganglia, 50:217
- methylspiperone, dopamine D<sub>2</sub> receptors, 50:217
- methylspiperone, methamphetamine psychosis, 50:217
- methylspiperone, positron emission tomography, 50:217

**Serotonin** continued

- obsessive-compulsive disorder, clinical response prediction, 50:25
  - obsessive-compulsive disorder, electroencephalography, 50:25
  - positron emission tomography, basal ganglia, 50:217
  - positron emission tomography, dopamine D<sub>2</sub> receptors, 50:217
  - positron emission tomography, methamphetamine psychosis, 50:217
  - positron emission tomography, methylspiperone, 50:217
- Single photon emission computed tomography**
- affective disorder, aging, 50:233
  - affective disorder, frontal lobes, 50:77
  - affective disorder, regional cerebral blood flow, 50:77, 50:233
  - aging, affective disorder, 50:233
  - aging, regional cerebral blood flow, 50:233
  - aging, unipolar depression, 50:233
  - catatonia, frontal lobes, 50:203
  - catatonia, iodoamphetamine, 50:203
  - catatonia, parietal lobes, 50:203
  - catatonia, regional cerebral blood flow, 50:203
  - catatonia, schizophrenia, 50:203
  - frontal lobes, affective disorder, 50:77
  - frontal lobes, catatonia, 50:203
  - frontal lobes, iodoamphetamine, 50:203
  - frontal lobes, parietal lobes, 50:203
  - frontal lobes, regional cerebral blood flow, 50:77, 50:177, 50:203
  - frontal lobes, schizophrenia, 50:203
  - frontal lobes, task difficulty, 50:177
  - frontal lobes, unipolar depression, 50:77
  - frontal lobes, Wisconsin Card Sorting Test, 50:177
  - image registration, magnetic resonance imaging, 50:57
  - image registration, region of interest, 50:57
  - iodoamphetamine, catatonia, 50:203
  - iodoamphetamine, frontal lobes, 50:203
  - iodoamphetamine, parietal lobes, 50:203
  - iodoamphetamine, regional cerebral blood flow, 50:203
  - iodoamphetamine, schizophrenia, 50:203
  - magnetic resonance imaging, image registration, 50:57
  - magnetic resonance imaging, region of interest, 50:57
  - parietal lobes, catatonia, 50:203
  - parietal lobes, frontal lobes, 50:203
  - parietal lobes, iodoamphetamine, 50:203

### **Single photon emission computed tomography continued**

- parietal lobes, regional cerebral blood flow, 50:203
- parietal lobes, schizophrenia, 50:203
- region of interest, image registration, 50:57
- region of interest, magnetic resonance imaging, 50:57
- regional cerebral blood flow, affective disorder, 50:77, 50:233
- regional cerebral blood flow, aging, 50:233
- regional cerebral blood flow, catatonia, 50:203
- regional cerebral blood flow, frontal lobes, 50:77, 50:177, 50:203
- regional cerebral blood flow, iodoamphetamine, 50:203
- regional cerebral blood flow, parietal lobes, 50:203
- regional cerebral blood flow, schizophrenia, 50:203
- regional cerebral blood flow, task difficulty, 50:177
- regional cerebral blood flow, unipolar depression, 50:77, 50:233
- regional cerebral blood flow, Wisconsin Card Sorting Test, 50:177
- schizophrenia, catatonia, 50:203
- schizophrenia, frontal lobes, 50:203
- schizophrenia, iodoamphetamine, 50:203
- schizophrenia, parietal lobes, 50:203
- schizophrenia, regional cerebral blood flow, 50:203
- task difficulty, frontal lobes, 50:177
- task difficulty, regional cerebral blood flow, 50:177
- task difficulty, Wisconsin Card Sorting Test, 50:177
- unipolar depression, affective disorder, 50:77, 50:233
- unipolar depression, aging, 50:233
- unipolar depression, frontal lobes, 50:77
- unipolar depression, regional cerebral blood flow, 50:77, 50:233
- Wisconsin Card Sorting Test, frontal lobes, 50:177
- Wisconsin Card Sorting Test, regional cerebral blood flow, 50:177
- Wisconsin Card Sorting Test, task difficulty, 50:177

### **Tardive dyskinesia**

- basal ganglia, magnetic resonance imaging, 50:33
- basal ganglia, motor learning, 50:33
- basal ganglia, schizophrenia, 50:33

### **Tardive dyskinesia continued**

- magnetic resonance imaging, basal ganglia, 50:33
  - magnetic resonance imaging, motor learning, 50:33
  - magnetic resonance imaging, schizophrenia, 50:33
  - motor learning, basal ganglia, 50:33
  - motor learning, magnetic resonance imaging, 50:33
  - motor learning, schizophrenia, 50:33
  - schizophrenia, basal ganglia, 50:33
  - schizophrenia, magnetic resonance imaging, 50:33
  - schizophrenia, motor learning, 50:33
- ### **Temporal lobes**
- aging, Alzheimer's disease, 50:163
  - aging, electroencephalography, 50:163
  - aging, motor performance, 50:163
  - Alzheimer's disease, aging, 50:163
  - Alzheimer's disease, electroencephalography, 50:163
  - Alzheimer's disease, motor performance, 50:163
  - electroencephalography, aging, 50:163
  - electroencephalography, Alzheimer's disease, 50:163
  - electroencephalography, motor performance, 50:163
  - magnetic resonance imaging, memory, 50:45
  - magnetic resonance imaging, schizophrenia, 50:45
  - memory, magnetic resonance imaging, 50:45
  - memory, schizophrenia, 50:45
  - motor performance, aging, 50:163
  - motor performance, Alzheimer's disease, 50:163
  - motor performance, electroencephalography, 50:163
  - schizophrenia, magnetic resonance imaging, 50:45
  - schizophrenia, memory, 50:45
- ### **Ventricle-brain ratio**
- aging, alcohol dependence, 50:257
  - aging, cerebrospinal fluid volume, 50:257
  - aging, computed tomography, 50:257
  - aging, magnetic resonance imaging, 50:257
  - alcohol dependence, aging, 50:257
  - alcohol dependence, cerebrospinal fluid volume, 50:257
  - alcohol dependence, computed tomography, 50:257
  - alcohol dependence, magnetic resonance imaging, 50:1, 50:257
  - basal ganglia, computed tomography, 50:143

**Ventricle-brain ratio continued**

basal ganglia, neurological soft signs, 50:143  
 basal ganglia, obsessive-compulsive disorder, 50:143  
 cerebrospinal fluid volume, aging, 50:257  
 cerebrospinal fluid volume, alcohol dependence, 50:257  
 cerebrospinal fluid volume, computed tomography, 50:257  
 cerebrospinal fluid volume, magnetic resonance imaging, 50:257  
 computed tomography, aging, 50:257  
 computed tomography, alcohol dependence, 50:257  
 computed tomography, basal ganglia, 50:143  
 computed tomography, cerebrospinal fluid volume, 50:257  
 computed tomography, head size, 50:121  
 computed tomography, magnetic resonance imaging, 50:121, 50:257  
 computed tomography, neurological soft signs, 50:143  
 computed tomography, obsessive-compulsive disorder, 50:143  
 head size, computed tomography, 50:121  
 head size, magnetic resonance imaging, 50:121  
 magnetic resonance imaging, aging, 50:257  
 magnetic resonance imaging, alcohol dependence, 50:1, 50:257  
 magnetic resonance imaging, cerebrospinal fluid volume, 50:257  
 magnetic resonance imaging, computed tomography, 50:121, 50:257  
 magnetic resonance imaging, head size, 50:121  
 magnetic resonance imaging, schizophrenia, 50:45  
 magnetic resonance imaging, Wechsler Memory Scale, 50:45

**Ventricle-brain ratio continued**

neurological soft signs, basal ganglia, 50:143  
 neurological soft signs, computed tomography, 50:143  
 neurological soft signs, obsessive-compulsive disorder, 50:143  
 obsessive-compulsive disorder, basal ganglia, 50:143  
 obsessive-compulsive disorder, computed tomography, 50:143  
 obsessive-compulsive disorder, neurological soft signs, 50:143  
 schizophrenia, magnetic resonance imaging, 50:45  
 schizophrenia, Wechsler Memory Scale, 50:45  
 Wechsler Memory Scale, magnetic resonance imaging, 50:45  
 Wechsler Memory Scale, schizophrenia, 50:45

**Wisconsin Card Sorting Test**  
 frontal lobes, regional cerebral blood flow, 50:177  
 frontal lobes, single photon emission computed tomography, 50:177  
 frontal lobes, task difficulty, 50:177  
 regional cerebral blood flow, frontal lobes, 50:177  
 regional cerebral blood flow, task difficulty, 50:177  
 single photon emission computed tomography, frontal lobes, 50:177  
 single photon emission computed tomography, task difficulty, 50:177  
 task difficulty, frontal lobes, 50:177  
 task difficulty, regional cerebral blood flow, 50:177  
 task difficulty, single photon emission computed tomography, 50:177